Chronic Gout Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major chronic gout markets are expected to exhibit a CAGR of 11.12% during 2024-2034.
The chronic gout market has been comprehensively analyzed in IMARC's new report titled "Chronic Gout Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic gout is a form of inflammatory arthritis characterized by recurrent attacks of severe joint pain, swelling, and redness. It is caused by the buildup of urate crystals within the joints due to elevated levels of uric acid in the blood. The most usually affected joint is the big toe, although various other joints like the knees, elbows, and wrists can also be involved. Symptoms typically include sudden, intense pain that often occurs at night, accompanied by swelling, redness, and warmth over the affected joint. These indications can persist and lead to joint damage and deformities if the condition is not effectively managed. Diagnosing chronic gout involves a combination of clinical evaluation and laboratory tests. Doctors may inquire about a patient's medical history, symptoms, and lifestyle factors, such as diet and alcohol consumption. Additionally, they may perform joint fluid analysis to check for the presence of urate crystals, which are characteristic of gout.
The escalating prevalence of the buildup of uric acid in the body, which leads to inflammation and intense pain, is primarily driving the chronic gout market. In addition to this, the inflating utilization of potent medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, and xanthine oxidase inhibitors is also creating a positive outlook for the market. These drugs aid in alleviating pain and reducing inflammation during gout attacks while also preventing the formation of urate crystals. Moreover, the widespread adoption of lifestyle modifications, including dietary adjustments and weight management, to help in decreasing the concentrations of uric acid in the blood and mitigating the frequency and severity of the condition is further bolstering the market growth. Apart from this, the increasing research into gene therapy, focused on manipulating or replacing genes that may be implicated in the dysfunction of purine metabolism, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of urate-lowering therapies like allopurinol and febuxostat, aimed at reducing uric acid levels in the blood, is also augmenting the market growth. Furthermore, the rising demand for biologic therapies, which target specific immune responses to control inflammation and improve the quality of life for patients, is expected to drive the chronic gout market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the chronic gout market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic gout and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic gout market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic gout market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic gout market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current chronic gout marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the chronic gout market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic gout market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic gout market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of chronic gout across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic gout by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic gout by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with chronic gout across the seven major markets?
What is the size of the chronic gout patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic gout?
What will be the growth rate of patients across the seven major markets?
Chronic Gout: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic gout drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic gout market?
What are the key regulatory events related to the chronic gout market?
What is the structure of clinical trial landscape by status related to the chronic gout market?
What is the structure of clinical trial landscape by phase related to the chronic gout market?
What is the structure of clinical trial landscape by route of administration related to the chronic gout market?
The chronic gout market has been comprehensively analyzed in IMARC's new report titled "Chronic Gout Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic gout is a form of inflammatory arthritis characterized by recurrent attacks of severe joint pain, swelling, and redness. It is caused by the buildup of urate crystals within the joints due to elevated levels of uric acid in the blood. The most usually affected joint is the big toe, although various other joints like the knees, elbows, and wrists can also be involved. Symptoms typically include sudden, intense pain that often occurs at night, accompanied by swelling, redness, and warmth over the affected joint. These indications can persist and lead to joint damage and deformities if the condition is not effectively managed. Diagnosing chronic gout involves a combination of clinical evaluation and laboratory tests. Doctors may inquire about a patient's medical history, symptoms, and lifestyle factors, such as diet and alcohol consumption. Additionally, they may perform joint fluid analysis to check for the presence of urate crystals, which are characteristic of gout.
The escalating prevalence of the buildup of uric acid in the body, which leads to inflammation and intense pain, is primarily driving the chronic gout market. In addition to this, the inflating utilization of potent medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, and xanthine oxidase inhibitors is also creating a positive outlook for the market. These drugs aid in alleviating pain and reducing inflammation during gout attacks while also preventing the formation of urate crystals. Moreover, the widespread adoption of lifestyle modifications, including dietary adjustments and weight management, to help in decreasing the concentrations of uric acid in the blood and mitigating the frequency and severity of the condition is further bolstering the market growth. Apart from this, the increasing research into gene therapy, focused on manipulating or replacing genes that may be implicated in the dysfunction of purine metabolism, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of urate-lowering therapies like allopurinol and febuxostat, aimed at reducing uric acid levels in the blood, is also augmenting the market growth. Furthermore, the rising demand for biologic therapies, which target specific immune responses to control inflammation and improve the quality of life for patients, is expected to drive the chronic gout market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the chronic gout market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic gout and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic gout market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic gout market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic gout market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current chronic gout marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the chronic gout market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic gout market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic gout market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of chronic gout across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic gout by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic gout by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with chronic gout across the seven major markets?
What is the size of the chronic gout patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic gout?
What will be the growth rate of patients across the seven major markets?
Chronic Gout: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic gout drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic gout market?
What are the key regulatory events related to the chronic gout market?
What is the structure of clinical trial landscape by status related to the chronic gout market?
What is the structure of clinical trial landscape by phase related to the chronic gout market?
What is the structure of clinical trial landscape by route of administration related to the chronic gout market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC GOUT - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHRONIC GOUT - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC GOUT - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CHRONIC GOUT - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC GOUT - UNMET NEEDS
10 CHRONIC GOUT - KEY ENDPOINTS OF TREATMENT
11 CHRONIC GOUT - MARKETED PRODUCTS
11.1 List of Chronic Gout Marketed Drugs Across the Top 7 Markets
11.1.1 Krystexxa (Pegloticase) - Horizon Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Adenuric (Febuxostat) - Menarini International
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Ilaris(Canakinumab) - Novartis
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 CHRONIC GOUT - PIPELINE DRUGS
12.1 List of Chronic Gout Pipeline Drugs Across the Top 7 Markets
12.1.1 SEL-212 - Selecta Biosciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AR882 - Arthrosi Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. CHRONIC GOUT - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHRONIC GOUT – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHRONIC GOUT - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Gout - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chronic Gout - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chronic Gout - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chronic Gout - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chronic Gout - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Gout - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chronic Gout - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chronic Gout - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Gout - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chronic Gout - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chronic Gout - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Gout - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chronic Gout - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chronic Gout - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Gout - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chronic Gout - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chronic Gout - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Gout - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chronic Gout - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chronic Gout - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Gout - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chronic Gout - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chronic Gout - Access and Reimbursement Overview
16 CHRONIC GOUT - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHRONIC GOUT MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHRONIC GOUT MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC GOUT - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHRONIC GOUT - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC GOUT - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CHRONIC GOUT - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC GOUT - UNMET NEEDS
10 CHRONIC GOUT - KEY ENDPOINTS OF TREATMENT
11 CHRONIC GOUT - MARKETED PRODUCTS
11.1 List of Chronic Gout Marketed Drugs Across the Top 7 Markets
11.1.1 Krystexxa (Pegloticase) - Horizon Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Adenuric (Febuxostat) - Menarini International
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Ilaris(Canakinumab) - Novartis
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 CHRONIC GOUT - PIPELINE DRUGS
12.1 List of Chronic Gout Pipeline Drugs Across the Top 7 Markets
12.1.1 SEL-212 - Selecta Biosciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AR882 - Arthrosi Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. CHRONIC GOUT - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHRONIC GOUT – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHRONIC GOUT - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Gout - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chronic Gout - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chronic Gout - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chronic Gout - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chronic Gout - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Gout - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chronic Gout - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chronic Gout - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Gout - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chronic Gout - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chronic Gout - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Gout - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chronic Gout - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chronic Gout - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Gout - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chronic Gout - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chronic Gout - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Gout - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chronic Gout - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chronic Gout - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Gout - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chronic Gout - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chronic Gout - Access and Reimbursement Overview
16 CHRONIC GOUT - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHRONIC GOUT MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHRONIC GOUT MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
